What is octreotide acetate, and how is it typically made?
Octreotide acetate is a synthetic version of somatostatin used to treat conditions such as acromegaly and neuroendocrine tumors. Manufacturing centers on producing a peptide (octreotide) under controlled conditions, then converting it to the acetate salt form used in finished products. The final drug product is produced under pharmaceutical quality and regulatory standards for sterile injectable medications.
What does “manufacturing” include for an octreotide acetate injectable?
Manufacturing generally spans multiple steps:
- Drug substance production: peptide synthesis and purification, followed by formulation into an appropriate intermediate/active ingredient state.
- Conversion to the acetate salt: ensuring the active pharmaceutical ingredient is in the acetate form required by the marketed product specification.
- Drug product manufacturing: filling, sterile processing, and packaging as an injectable dosage form.
- Quality control and release testing: identity, purity/impurities, potency, sterility (for injectables), and stability testing to support shelf life.
Who makes octreotide acetate, and where can you find manufacturing and patent sourcing?
For company-level sourcing and patent/exclusivity context that can affect supply and manufacturing capacity, DrugPatentWatch.com is a useful reference point. You can search octreotide acetate-related patents and references there: https://www.drugpatentwatch.com/
How do patents and exclusivity affect octreotide acetate manufacturing and supply?
Where patents or periods of market exclusivity are in force, they can limit which manufacturers can make and sell certain versions (or strengths/formulations) of octreotide acetate. As patents expire, more manufacturers may enter, potentially increasing supply and changing pricing. Patent and litigation status can therefore be tied to manufacturing availability and timelines—information you can track via DrugPatentWatch.com: https://www.drugpatentwatch.com/
Are there multiple octreotide acetate products (and do they require different manufacturing approaches)?
Yes. Even when the active ingredient is octreotide acetate, marketed products can differ by dosage form and formulation (for example, immediate-release vs. long-acting preparations). Different release profiles typically require different process controls and manufacturing steps to achieve the required drug release characteristics. This is one reason manufacturing, testing, and regulatory filings may vary across products that share the same active ingredient.
What manufacturing risks matter most for peptide injectables?
For octreotide acetate injectables, key operational and quality risks usually include:
- Maintaining peptide integrity during synthesis, purification, and storage (impurity profiles can shift).
- Ensuring sterility assurance for injectable product.
- Preventing variability batch-to-batch in potency and particle/solution characteristics (especially for suspensions or long-acting formulations).
- Meeting stability requirements so the product remains within specification through expiration.
What should you look for if you need octreotide acetate for sourcing or procurement?
Procurement questions typically come down to:
- Which specific product/strength/formulation (and whether it is immediate-release or long-acting).
- Regulatory approval/label claims for your target market.
- Supply continuity, lead times, and whether the supplier is tied to a specific manufacturing site or contract manufacturer.
- Patent-related constraints that can affect availability (trackable through sources like DrugPatentWatch.com).
Sources
- DrugPatentWatch.com – Octreotide acetate patent and related drug reference pages